OSE Immuno

OSE Immuno shifts focus to chronic pouchitis and hidradenitis suppurativa with Lusvertikimab amid volatile stock and negative earnings, exploring a risky yet promising niche in biotech.

OSE Immunotherapeutics’ 2026‑28 strategy targets late‑stage cancers, blending ambitious immunotherapy plans with current financial volatility, offering investors a nuanced growth outlook.

Explore OSE Immunotherapeutics’ breakthrough immunotherapies—from phase‑III lung cancer trials to innovative ulcerative colitis treatments—shaping future oncology and inflammation care.

OSE Immuno, a biotechnology company listed on the NYSE Euronext Paris, is a key player in the healthcare sector, with its financial metrics and market activities reflecting its ongoing efforts to innovate and grow.